Ionis Pharmaceuticals (IONS) Competitors $35.40 +1.65 (+4.89%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IONS vs. BHVN, RARE, PRGO, JAZZ, BHC, UTHR, INCY, NBIX, BMRN, and EXASShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "medical" sector. Ionis Pharmaceuticals vs. Biohaven Ultragenyx Pharmaceutical Perrigo Jazz Pharmaceuticals Bausch Health Companies United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Ionis Pharmaceuticals (NASDAQ:IONS) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Do insiders and institutionals hold more shares of IONS or BHVN? 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 2.7% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 16.0% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, IONS or BHVN? Ionis Pharmaceuticals has higher revenue and earnings than Biohaven. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$788M7.09-$366.29M-$2.44-14.51Biohaven$462.51M10.23-$408.17M-$9.35-5.01 Do analysts rate IONS or BHVN? Ionis Pharmaceuticals presently has a consensus target price of $60.65, suggesting a potential upside of 71.32%. Biohaven has a consensus target price of $63.42, suggesting a potential upside of 35.48%. Given Ionis Pharmaceuticals' higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.68Biohaven 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the MarketBeat Community believe in IONS or BHVN? Ionis Pharmaceuticals received 297 more outperform votes than Biohaven when rated by MarketBeat users. However, 66.89% of users gave Biohaven an outperform vote while only 60.21% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes69360.21% Underperform Votes45839.79% BiohavenOutperform Votes39666.89% Underperform Votes19633.11% Is IONS or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -44.58%. Ionis Pharmaceuticals' return on equity of -88.98% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-44.58% -88.98% -12.42% Biohaven N/A -225.12%-158.89% Which has more risk & volatility, IONS or BHVN? Ionis Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Does the media refer more to IONS or BHVN? In the previous week, Ionis Pharmaceuticals had 1 more articles in the media than Biohaven. MarketBeat recorded 12 mentions for Ionis Pharmaceuticals and 11 mentions for Biohaven. Biohaven's average media sentiment score of 0.72 beat Ionis Pharmaceuticals' score of 0.10 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIonis Pharmaceuticals and Biohaven tied by winning 9 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.33B$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-14.514.8389.0213.30Price / Sales7.09372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book8.437.876.085.74Net Income-$366.29M$153.61M$119.07M$225.93M7 Day Performance-4.92%-2.00%-1.84%-1.32%1 Month Performance-9.23%-7.47%-3.65%0.60%1 Year Performance-27.81%31.80%31.62%26.23% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.2328 of 5 stars$35.40+4.9%$60.65+71.3%-28.7%$5.33B$788M-14.51800BHVNBiohaven3.9207 of 5 stars$46.81+1.1%$63.42+35.5%+53.0%$4.68B$462.51M0.00239RAREUltragenyx Pharmaceutical4.6401 of 5 stars$46.40+2.8%$86.69+86.8%+17.9%$4.17B$434.25M0.001,276PRGOPerrigo4.9798 of 5 stars$27.15-0.3%$37.00+36.3%-10.8%$3.72B$4.66B-23.209,140Positive NewsJAZZJazz Pharmaceuticals4.9183 of 5 stars$119.24+2.1%$175.33+47.0%-1.2%$7.06B$3.83B16.792,800Analyst ForecastBHCBausch Health Companies3.4422 of 5 stars$8.20+0.1%$7.75-5.4%+16.3%$3.01B$8.76B0.0020,270Positive NewsUTHRUnited Therapeutics4.5219 of 5 stars$364.33+1.0%$370.86+1.8%+59.1%$16.10B$2.33B16.001,168Analyst RevisionPositive NewsINCYIncyte3.9 of 5 stars$71.05+0.7%$77.16+8.6%+29.9%$13.59B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$1.89B33.051,400Positive NewsBMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.81B$2.42B37.463,401Analyst RevisionEXASExact Sciences4.8868 of 5 stars$52.70-2.3%$74.47+41.3%-21.7%$9.98B$2.50B0.006,600Positive News Related Companies and Tools Related Companies BHVN Competitors RARE Competitors PRGO Competitors JAZZ Competitors BHC Competitors UTHR Competitors INCY Competitors NBIX Competitors BMRN Competitors EXAS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IONS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
